| Trade Names: | |
| Synonyms: | |
| Status: | Approved (1984) |
| Entry Type: | Small molecule |
| Molecule Category: | Salt |
| UNII: | Z6375YW9SF |
| Parent Compound: | NALTREXONE |
Structure
| InChI Key | RHBRMCOKKKZVRY-ITLPAZOVSA-N |
|---|---|
| Smile | |
| InChI |
|
Physicochemical Descriptors
| Property Name | Value |
|---|---|
| Molecular Formula | C20H24ClNO4 |
| Molecular Weight | 377.87 |
| AlogP | 1.53 |
| Hydrogen Bond Acceptor | 5.0 |
| Hydrogen Bond Donor | 2.0 |
| Number of Rotational Bond | 2.0 |
| Polar Surface Area | 70.0 |
| Molecular species | BASE |
| Aromatic Rings | 1.0 |
| Heavy Atoms | 25.0 |
Pharmacology
| Action | Mechanism of Action | Reference |
|---|---|---|
| ANTAGONIST | Opioid receptors; mu/kappa/delta antagonist | DailyMed |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Membrane receptor
Family A G protein-coupled receptor
Peptide receptor (family A GPCR)
Short peptide receptor (family A GPCR)
Opioid receptor
|
- | 1-1 | - | - | - | |
|
Transporter
Electrochemical transporter
SLC superfamily of solute carriers
SLC21/SLCO family of organic anion transporting polypeptides
|
- | - | - | - | 72 |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Chronic Pain | 3 | D059350 | ClinicalTrials |
| Charcot-Marie-Tooth Disease | 3 | D002607 | ClinicalTrials |
| Amphetamine-Related Disorders | 2 | D019969 | ClinicalTrials |
| Feeding and Eating Disorders | 2 | D001068 | ClinicalTrials |
| Severe Acute Respiratory Syndrome | 2 | D045169 | ClinicalTrials |
| Opioid-Related Disorders | 1 | D009293 | ClinicalTrials |
Related Entries
Adverse Reactions
System Organ Classification (SOC)
Cross References
| Resources | Reference |
|---|---|
| ChEBI | 134687 |
| ChEMBL | CHEMBL1201149 |
| FDA SRS | Z6375YW9SF |
| PubChem | 5388998 |
| SureChEMBL | SCHEMBL37713 |
CONTENTS